Overview

This trial is active, not recruiting.

Condition choroideremia
Treatment raav2.rep1
Phase phase 1/phase 2
Sponsor University of Oxford
Collaborator Oxford University Hospitals NHS Trust
Start date October 2011
End date February 2017
Trial size 14 participants
Trial identifier NCT01461213, 2009-014617-27, CHM09/01

Summary

- Primary objective: To assess the safety and tolerability of the AAV.REP1 vector, administered at two different doses to the retina in 12 patients with a diagnosis of choroideremia.

- Secondary Objective: To identify any therapeutic benefit as evidenced by a slowing down of the retinal degeneration assessed by functional and anatomical methods in the treated eye compared to the control eye 24 months after gene delivery.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Dose 1 = single subretinal injection of vector suspension containing approximately 10e10 rAAV2.REP1 genome particles. Six patients have now received Dose 1.
raav2.rep1 Adeno-associated viral vector
Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
(Experimental)
Dose 2 = single subretinal injection of vector suspension containing approximately 10e11 rAAV2.REP1 genome particles. Three patients thus far have received Dose 2.
raav2.rep1 Adeno-associated viral vector
Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.

Primary Outcomes

Measure
Visual acuity
time frame: 6 months

Secondary Outcomes

Measure
Microperimetry, OCT and fundus autofluorescence
time frame: 24 months

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: - Participant is willing and able to give informed consent for participation in the study, - Male aged 18 years or above, - Diagnosed with choroideraemia and in good health, - Active disease with SLO changes visible within the macula region, - Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study, - Vision at least 6/60 or better in the study eye. Exclusion Criteria: - Female and child participants (under the age of 18), - Men unwilling to use barrier contraception methods, if relevant, - Previous history of retinal surgery or ocular inflammatory disease (uveitis), - Grossly asymmetrical disease or other ocular morbidity which might confound use of the fellow eye as a long-term control, - Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study, - Participants who have participated in another research study involving an investigational product in the previous 12 weeks.

Additional Information

Official title An Open Label Dose Escalation Phase 1 Clinical Trial of Retinal Gene Therapy for Choroideraemia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
Principal investigator Miguel C Seabra, MD PhD
Description Detailed description may be found in the following scientific publication: Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial, The Lancet, Volume 383, Issue 9923, Pages 1129 - 1137 (29 March 2014). Links: www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62117-0/abstract ; http://dx.doi.org/doi:10.1016/S0140-6736(13)62117-0
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by University of Oxford.